Diaceutics PLC on Thursday said it has launched a ‘significant upgrade’ to its DXRX platform.

Shares in Diaceutics rose 4.3% to 105.88 pence each in London on Thursday afternoon.

The Belfast-based provider of diagnostic commercialisation services to pharmaceutical and biotechnology companies said the new function includes industry and de-identification, generative AI and new comprehensive US data sets that include data on social determinants of health.

‘Not only does the upgrade increase the power and efficiency of the platform, but also the applicability of Diaceutics’ subscription services into new parts of the precision medicine lifecycle, expanding the company’s addressable market,’ the firm explained.

DXRX is a diagnostic commercialisation platform for precision medicine.

Chief Data Officer Jordan Clark said: ‘Our Practise Gaps Study identified that a staggering 64.4% of patients do not get the right treatment. We seek to address that through the insights we provide, and today’s platform upgrade will empower healthcare providers to make timely and accurate treatment decisions, ultimately benefiting more patients.’

Copyright 2024 Alliance News Ltd. All Rights Reserved.